Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments: 2016-2023

Historic Change in Acquisitions & Divestments for Cartesian Therapeutics (RNAC) over the last 7 years, with Dec 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Change in Acquisitions & Divestments rose 182.54% to $28.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $48.0 million, marking a year-over-year increase of 26.53%. This contributed to the annual value of $28.3 million for FY2023, which is 43.42% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $28.3 million for FY2023, which was up 43.42% from $19.7 million recorded in FY2022.
  • Cartesian Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $28.3 million for FY2023, and its period low was $16.4 million during FY2019.
  • In the last 3 years, Cartesian Therapeutics' Change in Acquisitions & Divestments had a median value of $19.7 million in 2022 and averaged $21.5 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Change in Acquisitions & Divestments crashed by 60.75% in 2019 and then surged by 43.42% in 2023.
  • Cartesian Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $16.4 million in 2019, then reached $16.4 million in 2021, then climbed by 20.12% to $19.7 million in 2022, then soared by 43.42% to $28.3 million in 2023.